Discontinued — last reported Q1 '26
Lagevrio — Sales
Merck & Co. Lagevrio — Sales decreased by 50.9% to $28.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 72.5%, from $102.00M to $28.00M. Over 4 years (FY 2021 to FY 2025), Lagevrio — Sales shows a downward trend with a -20.5% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates strong market demand or effective commercialization of the therapeutic, while a decrease suggests waning demand or the impact of shifting public health landscapes.
Detailed definition
This metric represents the total net revenue generated from the sale of a specific antiviral therapeutic product within...
Peer comparison
Comparable to revenue metrics for specific blockbuster drugs or pandemic-related therapeutics at other large-cap pharmaceutical companies.
mrk_segment_lagevrio_salesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $0.00 | $952.00M | $3.25B | $1.18B | $436.00M | $824.00M | $392.00M | $203.00M | $640.00M | $193.00M | $350.00M | $110.00M | $383.00M | $121.00M | $102.00M | $83.00M | $138.00M | $57.00M | $28.00M |
| QoQ Change | — | — | — | +241.1% | -63.8% | -63.0% | +89.0% | -52.4% | -48.2% | +215.3% | -69.8% | +81.3% | -68.6% | +248.2% | -68.4% | -15.7% | -18.6% | +66.3% | -58.7% | -50.9% |
| YoY Change | — | — | — | — | — | — | -13.4% | -87.9% | -82.8% | +46.8% | -76.6% | -10.7% | -45.8% | -40.2% | -37.3% | -70.9% | -24.5% | -64.0% | -52.9% | -72.5% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Merck & Co.'s lagevrio — sales?
- Merck & Co. (MRK) reported lagevrio — sales of $28.00M in Q1 2026.
- How has Merck & Co.'s lagevrio — sales changed year-over-year?
- Merck & Co.'s lagevrio — sales decreased by 72.5% year-over-year, from $102.00M to $28.00M.
- What is the long-term trend for Merck & Co.'s lagevrio — sales?
- Over 4 years (2021 to 2025), Merck & Co.'s lagevrio — sales has grown at a -20.5% compound annual growth rate (CAGR), from $952.00M to $380.00M.
- What does lagevrio — sales mean?
- The total revenue earned from the sales of the company's specific antiviral medication.